Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | García-Iglesias, C. (Cristina) | - |
dc.creator | Puledda, F. (Francesca) | - |
dc.creator | Echavarria-Iñiguez, A. (Ana) | - |
dc.creator | González-Osorio, Y. (Yesica) | - |
dc.creator | Sierra-Mencia, A. (Álvaro) | - |
dc.creator | Recio-García, A. (Andrea) | - |
dc.creator | González-Celestino, A. (Ana) | - |
dc.creator | Valle-Peñacoba, G. (Gonzálo) | - |
dc.creator | Irimia, P. (Pablo) | - |
dc.creator | Guerrero-Peral, A.L. (Ángel Luis) | - |
dc.creator | García-Azorín, D. (David) | - |
dc.date.accessioned | 2023-02-09T12:41:05Z | - |
dc.date.available | 2023-02-09T12:41:05Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | García-Iglesias, C.; Puledda, F.; Echavarria-Iñiguez, A.; et al. "Treatment of primary nummular headache: a series of 183 patients from the NUMITOR study". Journal of Clinical Medicine. 12 (1), 2023, 122 | es |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://hdl.handle.net/10171/65394 | - |
dc.description.abstract | Nummular headache (NH) is a primary headache characterized by superficial coin-shaped pain. NUMITOR (NCT 05475769) is an observational study evaluating the responder rate of preventive drugs in NH patients. The treatment response was assessed between weeks 8 and 12 compared with the baseline. Patients were included between February 2002 and October 2022. Demographic and clinical variables were assessed; treatment response was estimated by 50%, 30%, and 75% responder rates and treatment discontinuation due to inadequate tolerability. A total of 183 out of 282 patients fulfilled eligibility criteria and completed the study. Patients were aged 49.5 (standard deviation (SD): 16.8) years, and 60.7% were female. NH phenotype was a parietal circular pain of four centimeters' diameter, moderate intensity, and oppressive quality. At baseline, patients had 25 (interquartile range) pain days per month. Preventive treatment was used by 114 (62.3%) patients. The highest 50% and 75% responder rates corresponded to onabotulinumtoxinA (62.5%, 47.5%), followed by gabapentin (43.7%, 35.2%). Oral preventive drugs were not tolerated by 12.9-25%. The present study provides class IV evidence of the effectiveness of oral preventive drugs and onabotulinumtoxinA in the treatment of primary NH. OnabotulinumtoxinA was the most effective and best-tolerated drug, positioning it as first-line treatment of NH. | - |
dc.description.sponsorship | The study was funded by the Regional Health Administration (Gerencia Regional de Salud, SACYL, Castilla y León, grant number: GRS 2416/A/21). | - |
dc.language.iso | en | - |
dc.rights | info:eu-repo/semantics/openAccess | - |
dc.subject | Headache disorders | - |
dc.subject | Nummular headache | - |
dc.subject | Epicranial headache | - |
dc.title | Treatment of primary nummular headache: a series of 183 patients from the NUMITOR study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.description.note | This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license | - |
dc.identifier.doi | 10.3390/jcm12010122 | - |
dadun.citation.number | 1 | - |
dadun.citation.publicationName | Journal of Clinical Medicine | - |
dadun.citation.startingPage | 122 | - |
dadun.citation.volume | 12 | - |
dc.identifier.pmid | 36614923 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.